Table 4.
Population equally distributed equivalent health impact at an opportunity cost threshold of £30,000 per quality-adjusted life-year
| TA520 atezolizumab | TA536 alectinib | |
|---|---|---|
| Evaluating changes in population health (change in equity not included) | ||
| Baseline population QALE (QALEb*N) (1) | 3,942,667,355 QALYs | 3,942,667,355 QALYs |
| Post-decision population QALE (QALEp*N) (2) | 3,942,665,467 QALYs | 3,942,667,446 QALYs |
| Incremental population QALE (∆QALE*N) (3)=(2)-(1) | − 1,888 QALYs | 91 QALYs |
| Evaluating changes in equity-weighted health (changes in health and health equity both included) | ||
| Baseline population EDEH (equity-weighted QALE) (EDEHb*N) (4) | 3,863,434,366 QALYs | 3,863,434,366 QALYs |
| Post-decision population EDEH (EDEHp*N) (5) | 3,863,432,534 QALYs | 3,863,434,528 QALYs |
| Incremental population EDEH (∆EDEH*N) (6) | − 1,833 QALYs | 162 QALYs |
| Health equity impact | ||
| Population equity impact (incremental EDEH – incremental QALE) (6–3) | 56 QALYs | 71 QALYs |
EDEH equally distributed equivalent health, EDEHb baseline equally distributed equivalent health per person, EDEHp post-decision equally distributed equivalent health per person, ∆EDEH difference in EDEH between post-decision and baseline, N population of England, QALE quality-adjusted life expectancy, QALEb baseline quality-adjusted life expectancy at birth per person, QALEp post-decision quality-adjusted life expectancy at birth per person, ∆QALE difference in QALE between post-decision and baseline, TA technology appraisal